The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.

Journal of Gastroenterology
Tsugiko OzeNorio Hayashi

Abstract

Which patients with hepatitis C virus (HCV) genotype 1 can benefit from extended treatment with pegylated interferon (Peg-IFN) plus ribavirin is unknown, although the overall sustained virologic response (SVR) rate has been shown to improve in patients with a late virologic response (LVR), defined as detectable serum HCV RNA at week 12 and undetectable at week 24. Among 1163 chronic hepatitis C patients with genotype 1 treated with Peg-IFN plus ribavirin combination therapy, 213 patients with an LVR were examined in this study. In addition, we selected 81 patients of matched sex and age from each of the 48- and 72-week treatment groups, using the propensity score, to compare the efficacy of the two treatment durations. With 72-week treatment, the timing of HCV RNA disappearance and the hemoglobin level at baseline showed a strong correlation with the SVR on multivariate analysis. Earlier HCV RNA disappearance was associated with a better SVR rate, regardless of the ribavirin dose (HCV RNA disappearance at week 16, 74%; at week 20, 52%; and at week 24, 31%, p = 0.01). The SVR rate with 72-week treatment was higher than that with 48-week treatment, irrespective of age, sex, or the platelet value, and, especially in aged patients ...Continue Reading

References

Oct 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K KiyosawaR H Purcell
May 15, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A KasaharaK Okita
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Mar 5, 2004·Annals of Internal Medicine·Stephanos J HadziyannisUNKNOWN PEGASYS International Study Group
Feb 28, 2006·Journal of Gastroenterology·Norio Hayashi, Tetsuo Takehara
Nov 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brian L PearlmanSophia Saifee
Dec 12, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Alessandra MangiaAngelo Andriulli
Feb 12, 2009·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Mika KurokawaNorio Hayashi
Mar 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN American Association for the Study of Liver Diseases
Jul 25, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN IDEAL Study Team
Sep 15, 2009·Nature Genetics·Vijayaprakash SuppiahJacob George
Sep 18, 2009·Nature·David L ThomasMary Carrington
Nov 17, 2009·Gastroenterology·Peter FerenciUNKNOWN Austrian Hepatitis Study Group
Aug 5, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Maria ButiUNKNOWN SUCCESS Study Investigators

❮ Previous
Next ❯

Citations

Jan 22, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Tsugiko OzeTetsuo Takehara
Jan 22, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·
Jun 12, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hiroaki OkushinKoichi Uesaka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.